Cargando…
Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients
BACKGROUND: In 2019, a highly pathogenic coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surfaced and resulted in the outbreak of coronavirus disease 2019 (COVID-19). With the aim of finding effective drugs to fight against the disease, several trials have been conduct...
Autores principales: | de Souza, Sávio Bastos, Cabral, Paula Gebe Abreu, da Silva, Renato Martins, Arruda, Raul Ferraz, Cabral, Sheila Passos de Figueiredo, de Assis, Arícia Leone Evangelista Monteiro, Viana Junior, Antônio Brazil, Degrave, Wim Maurits Sylvain, Moreira, Aline dos Santos, Silva, Cléber Glória, Chang, Junbiao, Lei, Pingsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620601/ https://www.ncbi.nlm.nih.gov/pubmed/37928473 http://dx.doi.org/10.3389/fmed.2023.1215916 |
Ejemplares similares
-
Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19
por: da Silva, Renato Martins, et al.
Publicado: (2023) -
Azvudine (FNC): a promising clinical candidate for COVID-19 treatment
por: Yu, Bin, et al.
Publicado: (2020) -
The first Chinese oral anti-COVID-19 drug Azvudine launched
por: Yu, Bin, et al.
Publicado: (2022) -
A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study
por: Ren, Zhigang, et al.
Publicado: (2020) -
Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials
por: Zhu, Ke-Wei
Publicado: (2023)